About the Company

A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company's primary focus is on its lead product candidate, APF530, which has completed a pivotal Phase 3 clinical trial for the prevention of CINV. An NDA for APF530 was filed in May 2009.  The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems.

Recent Press Releases

06/03/09 - A.P. Pharma Receives Extension for Nasdaq Listing Compliance

06/01/09 - A.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical Oncology

05/29/09 - A.P. Pharma Announces Additional Restructuring Effort

More Releases >>